<DOC>
	<DOC>NCT00034606</DOC>
	<brief_summary>The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.</brief_summary>
	<brief_title>Comparing 3 Schedules of Alimta Plus Gemzar</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis of nonsmall lung cancer No prior chemotherapy Able to care for self An ongoing infection Pregnancy or breast feeding Other serious medical condition Cancer that has spread to the brain Inability to take folic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>neoplasm</keyword>
	<keyword>non-small</keyword>
	<keyword>chemotherapy</keyword>
</DOC>